330 related articles for article (PubMed ID: 8677449)
1. Ifosfamide in the treatment of ovarian cancer.
Markman M
Semin Oncol; 1996 Jun; 23(3 Suppl 6):47-9. PubMed ID: 8677449
[TBL] [Abstract][Full Text] [Related]
2. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Markman M; Kennedy A; Sutton G; Hurteau J; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 1998 Aug; 70(2):272-4. PubMed ID: 9740704
[TBL] [Abstract][Full Text] [Related]
4. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
Markman M
Semin Oncol; 1995 Jun; 22(3 Suppl 6):88-9. PubMed ID: 7597438
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
6. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide in the treatment of germ cell tumors.
Nichols CR
Semin Oncol; 1996 Jun; 23(3 Suppl 6):65-73. PubMed ID: 8677452
[TBL] [Abstract][Full Text] [Related]
8. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE
Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel in salvage therapy for germ cell tumors.
Motzer RJ
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
[TBL] [Abstract][Full Text] [Related]
11. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
12. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
Dorval T; Soussain C; Beuzeboc P; Garcia-Giralt E; Jouve M; Livartowski A; Mosseri V; Palangié T; Scholl S; Sastre X; Pouillart P
J Infus Chemother; 1996; 6(1):47-9. PubMed ID: 8748008
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
